Wells Fargo analyst David Maris says that while fighting the FDA or Centers for Medicare and Medicaid Services is "rarely lucrative" for companies, he understands why Mallinckrodt would want to defend itself in court. While Mallinckrodt is making progress with its pipeline, "unexpected negative news continues to add to investor uncertainty," Maris tells investors in a research note. The analyst expects the stock to "bounce off these levels," but he adds that management "needs to resolve, not add, overhangs to meaningfully rebuild investor confidence." Maris keeps a Market Perform rating on Mallinckrodt. The stock in midday trading is down 27%, or $3.52, to $9.51.